Nurix Therapeutics Inc - Asset Resilience Ratio
Nurix Therapeutics Inc (NRIX) has an Asset Resilience Ratio of 67.06% as of August 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NRIX net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Nurix Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see NRIX asset base.
Liquid Assets Composition Over Time
This chart breaks down Nurix Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Nurix Therapeutics Inc to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $350.39 Million | 67.06% |
| Total Liquid Assets | $350.39 Million | 67.06% |
Asset Resilience Insights
- Very High Liquidity: Nurix Therapeutics Inc maintains exceptional liquid asset reserves at 67.06% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nurix Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Nurix Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS |
Biotechnology | 78.33% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 23.94% |
Annual Asset Resilience Ratio for Nurix Therapeutics Inc (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Nurix Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-11-30 | 74.64% | $499.59 Million | $669.34 Million | +9.04pp |
| 2023-11-30 | 65.60% | $233.28 Million | $355.60 Million | +6.90pp |
| 2022-11-30 | 58.71% | $244.67 Million | $416.76 Million | +13.57pp |
| 2021-11-30 | 45.14% | $215.21 Million | $476.77 Million | +4.32pp |
| 2020-11-30 | 40.82% | $161.79 Million | $396.34 Million | +34.23pp |
| 2019-11-30 | 6.59% | $2.90 Million | $44.05 Million | -23.03pp |
| 2018-11-30 | 29.62% | $13.45 Million | $45.40 Million | -- |
About Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-ce… Read more